Primary Care

Top Story

Cyclophosphamide 'not dead yet' for ANCA-associated vasculitis

Cyclophosphamide 'not dead yet' for ANCA-associated vasculitis
October 21, 2019
FDA News

Triple therapy approved to treat cystic fibrosis

October 21, 2019
The FDA announced it has approved elexacaftor/ivacaftor/tezacaftor, the first triple combination therapy for patients with the most common cystic fibrosis mutation. The…
In the Journals

Boys with inattention, hyperactivity have higher risk for TBIs

October 21, 2019
Boys who exhibit inattention, hyperactivity and externalizing problems are at an increased risk for traumatic brain injury, or TBI, and evidence-based treatments to…
In the Journals

Child mental health status may be closely linked to father's

October 21, 2019
Children whose fathers have poor mental health are more than twice as likely also to have poor mental health, according to findings published in Health Equity.
More Headlines »